JP2023519908A5 - - Google Patents
Info
- Publication number
- JP2023519908A5 JP2023519908A5 JP2022558492A JP2022558492A JP2023519908A5 JP 2023519908 A5 JP2023519908 A5 JP 2023519908A5 JP 2022558492 A JP2022558492 A JP 2022558492A JP 2022558492 A JP2022558492 A JP 2022558492A JP 2023519908 A5 JP2023519908 A5 JP 2023519908A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cells
- receptor
- cancer
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001275P | 2020-03-28 | 2020-03-28 | |
| US63/001,275 | 2020-03-28 | ||
| PCT/US2021/024123 WO2021202232A1 (en) | 2020-03-28 | 2021-03-25 | Cell immunotherapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519908A JP2023519908A (ja) | 2023-05-15 |
| JP2023519908A5 true JP2023519908A5 (https=) | 2024-03-18 |
| JP7773789B2 JP7773789B2 (ja) | 2025-11-20 |
Family
ID=77929404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558492A Active JP7773789B2 (ja) | 2020-03-28 | 2021-03-25 | 癌の治療のための細胞免疫療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230074303A1 (https=) |
| EP (1) | EP4125950A4 (https=) |
| JP (1) | JP7773789B2 (https=) |
| KR (1) | KR20220162157A (https=) |
| CN (1) | CN115551522A (https=) |
| AU (1) | AU2021246671A1 (https=) |
| BR (1) | BR112022018668A2 (https=) |
| CA (1) | CA3176258A1 (https=) |
| MX (1) | MX2022012050A (https=) |
| WO (1) | WO2021202232A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172514A1 (en) * | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| KR20250166262A (ko) * | 2023-03-24 | 2025-11-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 향상된 항종양 기억 반응을 갖는 조작된 자연 살해 세포 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3326467B1 (en) * | 2011-09-16 | 2020-03-11 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2015154012A1 (en) * | 2014-04-03 | 2015-10-08 | Memorial Sloan-Kettering Cancer Center | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations |
| US11154572B2 (en) | 2015-06-05 | 2021-10-26 | Board Of Regents, The University Of Texas System | Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type |
| EP3307876B1 (en) | 2015-06-10 | 2023-09-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| CN108060137B (zh) | 2017-12-26 | 2021-07-02 | 博生吉医药科技(苏州)有限公司 | Il7和il21修饰的nk92细胞、制备方法及其应用 |
| EP3741861A4 (en) | 2018-01-19 | 2021-12-08 | Cafa Therapeutics Limited | SYNNOTCH RECEPTOR REGULATED EXPRESSION OF IL12 |
| IL321548A (en) * | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| JP7241161B2 (ja) | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| CN110760480B (zh) * | 2019-07-09 | 2021-07-02 | 杭州师范大学 | 一种抗肿瘤nk细胞及其制备方法 |
| WO2021101467A1 (en) * | 2019-11-19 | 2021-05-27 | Acibadem Mehmet Ali̇ Aydinlar Üni̇versi̇tesi̇ | A method for redesign and expansion of nk92 cells for use in immunotherapy |
-
2021
- 2021-03-25 CA CA3176258A patent/CA3176258A1/en active Pending
- 2021-03-25 CN CN202180024929.6A patent/CN115551522A/zh active Pending
- 2021-03-25 JP JP2022558492A patent/JP7773789B2/ja active Active
- 2021-03-25 US US17/904,408 patent/US20230074303A1/en active Pending
- 2021-03-25 MX MX2022012050A patent/MX2022012050A/es unknown
- 2021-03-25 WO PCT/US2021/024123 patent/WO2021202232A1/en not_active Ceased
- 2021-03-25 KR KR1020227037750A patent/KR20220162157A/ko active Pending
- 2021-03-25 BR BR112022018668A patent/BR112022018668A2/pt unknown
- 2021-03-25 EP EP21779007.0A patent/EP4125950A4/en active Pending
- 2021-03-25 AU AU2021246671A patent/AU2021246671A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rezvani et al. | Engineering natural killer cells for cancer immunotherapy | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| JP2021519061A5 (https=) | ||
| JP2021513347A5 (https=) | ||
| IL276593A (en) | Improved methods for producing adoptive cell therapies | |
| JP2021505131A5 (https=) | ||
| JP2022548943A5 (https=) | ||
| JP2022550899A5 (https=) | ||
| JP2022541441A5 (https=) | ||
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| JP2023505206A5 (https=) | ||
| JP2021525731A5 (https=) | ||
| JP2022510207A5 (https=) | ||
| JP2022531222A5 (https=) | ||
| JP2023552998A5 (https=) | ||
| RU2018134771A (ru) | Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение | |
| JP2020506700A5 (https=) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| JP2017513470A5 (https=) | ||
| KR20170067773A (ko) | Car 발현 벡터 및 car 발현 t 세포 | |
| JP2023524047A5 (https=) | ||
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| JP2016510597A5 (https=) | ||
| JP2023519908A5 (https=) |